Edition:
United States

Acorda Therapeutics Inc (ACOR.OQ)

ACOR.OQ on NASDAQ Stock Exchange Global Select Market

23.70USD
18 May 2018
Change (% chg)

$-0.45 (-1.86%)
Prev Close
$24.15
Open
$24.20
Day's High
$24.20
Day's Low
$23.45
Volume
89,099
Avg. Vol
154,704
52-wk High
$29.50
52-wk Low
$13.65

Chart for

About

Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra... (more)

Overall

Beta: 1.60
Market Cap(Mil.): $1,132.97
Shares Outstanding(Mil.): 46.91
Dividend: --
Yield (%): --

Financials

  ACOR.OQ Industry Sector
P/E (TTM): -- 223.30 32.53
EPS (TTM): -4.32 -- --
ROI: -17.57 -8.07 12.63
ROE: -32.54 -10.87 14.50

BRIEF-Hls Therapeutics Announces Qtrly Net Loss $0.19 Per Common Share

* QTRLY NET LOSS $0.19 PER COMMON SHARE Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

May 16 2018

BRIEF-vTv Therapeutics Q1 GAAP Loss Per Share $0.30

* VTV THERAPEUTICS REPORTS 2018 FIRST QUARTER FINANCIAL AND OPERATIONAL RESULTS AND RECENT HIGHLIGHTS

May 15 2018

BRIEF-Acer Therapeutics Q1 Loss Per Share $0.53

* ACER THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

May 14 2018

BRIEF-Abeona Therapeutics Posts Q1 Loss Of $0.18 Per Share

* ABEONA THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS

May 11 2018

BRIEF-Acorda Therapeutics Reports Q1 Non-GAAP Earnings Per Share Of $0.14

* ACORDA PROVIDES FINANCIAL AND PIPELINE UPDATE FOR FIRST QUARTER 2018

May 02 2018

BRIEF-Axsome Therapeutics Appoints Nick Pizzie, Cpa, Mba, As Chief Financial Officer

* AXSOME THERAPEUTICS APPOINTS NICK PIZZIE, CPA, MBA, AS CHIEF FINANCIAL OFFICER

Apr 19 2018

BRIEF-Abeona Therapeutics Appoints Carsten Thiel, Ph.D., As Chief Executive Officer

* ABEONA THERAPEUTICS APPOINTS CARSTEN THIEL, PH.D., AS CHIEF EXECUTIVE OFFICER

Apr 02 2018

BRIEF-Acorda Files Marketing Authorization Application For Inbrija

* ACORDA FILES MARKETING AUTHORIZATION APPLICATION FOR INBRIJA™ (LEVODOPA INHALATION POWDER)

Mar 26 2018

BRIEF-Leap Therapeutics Provides Dkn-01 Program Update

* LEAP THERAPEUTICS PROVIDES DKN-01 PROGRAM UPDATE AND ANNOUNCES SCIENTIFIC PRESENTATIONS AT AACR ANNUAL MEETING

Mar 14 2018

BRIEF-Acorda Enters Into Cooperation Agreement With Scopia

* ACORDA THERAPEUTICS INC - ‍ UNDER TERMS, AFTER 2018 ANNUAL MEETING AND UNTIL JAN 1, 2019, SCOPIA IS ENTITLED TO APPOINT 2 DIRECTORS TO CO'S BOARD​

Feb 28 2018

Earnings vs. Estimates